7 Critical Advances in Emulsion Dynamics for cTACE & NBCA Embolization
⚡ At a glance — Emulsion dynamics in cTACE and NBCA snapshot
- Optimal w/o ratio: 1:4 aqueous-to-Lipiodol (stable >72 h)
- Unstable o/w ratio: 1:1 (phase separation <15 min)
- Mixing exchanges: Minimum 20 back-and-forth pumps
- Optimal droplet size: 70–100 μm
- cTACE CR (tumors <3 cm): 84.2% at 1 month
- DEB-TACE CR (tumors <3 cm): 35.7% at 1 month
- NBCA 1:1 cure time: 3.2 seconds
- NBCA 1:4 cure time: >10 seconds (distal penetration)
- PC stopcock failure: 15–60 minutes Lipiodol contact
- SATMix cost reduction: 66% vs. traditional kits
⚠ Primary procedural pitfall: Using standard polycarbonate stopcocks and syringes with Lipiodol causes environmental stress cracking within 15–60 minutes, risking catastrophic device failure, air embolism, and chemical contamination. Only Lipiodol-resistant polymers are safe.
📋 Table of contents
- Introduction to precision interventional oncology
- Emulsion science and stability determinants in cTACE
- 2026 society guidelines: cTACE and glue embolization
- Clinical comparative efficacy: conventional versus modern alternatives
- NBCA glue embolization: polymerization dynamics and clinical applications
- The polycarbonate vulnerability: material science in 2026
- Standardized delivery: the SATMix system
- Future applications and evolving horizons
- Further reading
- Conclusion
- References
Introduction to precision interventional oncology
Interventional radiology (IR) has solidified its position at the center of precision oncology and vascular medicine. As of 2026, the management of hypervascular tumors — particularly hepatocellular carcinoma (HCC) — and complex vascular anomalies like arteriovenous malformations (AVMs) is governed by sophisticated liquid embolic protocols. Central to these procedures is the physicochemical stability of emulsions: specifically, ethiodized oil (Lipiodol)-drug mixtures in conventional transarterial chemoembolization (cTACE) and N-butyl cyanoacrylate (NBCA) glue mixtures in vascular obliteration.
Despite the clinical success of these modalities, procedural outcomes are strictly dictated by the structural integrity of delivery systems and the stability of the embolic mixtures. A stable water-in-oil (w/o) emulsion ensures that chemotherapy is sequestered within the tumor interstitium rather than released systemically. An unstable oil-in-water (o/w) mixture, by contrast, leads to rapid drug efflux, subtherapeutic intra-tumoral concentrations, and increased systemic toxicity. This article provides the complete technical and clinical framework for mastering emulsion dynamics in cTACE and NBCA procedures: the physicochemical principles, 2026 society guidelines, comparative efficacy data, material science considerations, and the standardized delivery systems that ensure reproducible outcomes.
The success of cTACE and NBCA embolization is not merely a function of operator skill — it is fundamentally a materials science and standardization problem. Variability in mixing technique, stopcock quality, polymer composition, and emulsion type directly determines whether a procedure achieves complete response or requires repeat intervention. Departments that treat emulsion preparation as a governed, protocol-driven process consistently outperform those that rely on ad-hoc manual techniques.
💉 Standardize emulsion preparation with Lipiodol-resistant systems
SATMED Health’s SATMix single-use mixing kit features 24-hour Lipiodol-resistant polymers, a closed-loop 4-port stopcock, and standardized 20-exchange protocol — eliminating variability and device failure in every cTACE and glue embolization case.
Explore SATMix Solutions →Emulsion science and stability determinants in cTACE
Understanding emulsion dynamics in cTACE and NBCA begins with the physicochemical behaviour of ethiodized oil under clinical mixing conditions. The principles that govern Lipiodol-drug stability directly determine whether a procedure achieves therapeutic intra-tumoral drug concentrations or risks systemic toxicity.
Physicochemical characteristics and stability determinants
The efficacy of cTACE is intrinsically linked to the behavior of ethiodized oil, which serves as a drug vehicle, a transient embolic agent, and a radiopaque marker. The successful administration of cTACE requires the creation of a stable emulsion between the oily Lipiodol and an aqueous chemotherapy solution (e.g., doxorubicin, epirubicin, or miriplatin).
The stability of a Lipiodol-drug emulsion determines drug delivery efficiency and systemic toxicity. Clinically, water-in-oil (w/o) emulsions are superior to oil-in-water (o/w) configurations because the continuous oily phase “shields” the drug, ensuring it is carried directly into the tumor interstitium and sequestered there.[1]
Key variables dictating stability include:
- Aqueous-to-Lipid Phase Ratio: Research indicates that a higher Lipiodol content significantly enhances stability. Emulsions with a 1:4 aqueous-to-lipid ratio can remain stable for more than 72 hours, while a 1:1 ratio often results in phase separation within 15 minutes.[2]
- Aqueous Phase Composition: The addition of non-ionic contrast agents, such as iohexol (Omnipaque), improves stability by increasing drug solubility (exceeding 69 mg/mL) and modifying the viscosity of the aqueous phase.[3]
- Mechanical Energy: Standard 2026 protocols require a minimum of 20 vigorous back-and-forth pumping exchanges through a 3-way or 4-way stopcock to achieve optimal droplet sizes between 70 and 100 μm.[4]
The drop test: a bedside standard for quality control
The “drop test” remains the mandatory qualitative assessment in 2026 for verifying emulsion type. A single droplet of the emulsion is placed into a container of saline. In a true w/o emulsion, the droplet maintains its shape and sinks or floats without dispersing. If the droplet dissolves or creates a cloudy solution, it indicates an o/w mixture, which is unsuitable for administration as it leads to rapid systemic drug efflux.
Never administer a cTACE emulsion without performing the drop test. An o/w mixture will deliver chemotherapy systemically rather than intra-tumorally, increasing toxicity without therapeutic benefit. Document the drop test result in the procedural record as a standard quality assurance step.
🔬 Eliminate emulsion variability with engineered mixing systems
SATMix’s standardized 20-exchange protocol and closed-loop architecture produce consistent w/o emulsions every time — removing the guesswork and manual variability that compromise cTACE outcomes.
Learn About SATMix →2026 society guidelines: cTACE and glue embolization
EASL and BCLC 2026 updates for HCC
The European Association for the Study of the Liver (EASL) and the Barcelona Clínic Liver Cancer (BCLC) group updated their guidelines in 2025/2026, presented at the Liver Cancer Summit in Paris.[5]
- Multiparametric Decision-Making: Guidelines now incorporate a multiparametric model, personalizing treatment based on tumor burden, liver function, and patient performance status.
- Radical TACE Strategy: Superselective cTACE (ss-cTACE) is recommended for tumors smaller than 5 cm involving a maximum of two segments.
- “On-Demand” Treatment: Experts recommend a minimum of two sequential cTACE procedures in a treatment cycle, with an “on-demand” approach (up to 3–4 times per year) based on tumor response.
CIRSE 2026 standards of practice
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) released several landmark documents in 2026:[6]
- Endovascular Treatment of Acute Pulmonary Embolism: New standards led by A. Basile emphasize early intervention and the rise of PE response teams.
- Material Standardization: CIRSE emphasizes the use of Lipiodol-resistant polymers for stopcocks and syringes to prevent device failure and air embolism during high-pressure injections.
SIR 2026 clinical practice guidance
The Society of Interventional Radiology (SIR) 2026 Annual Meeting in Toronto introduced new practice guidance for chronic conditions:[7]
- Chronic Pelvic Pain: SIR published evidence-based guidance for the treatment of venous-origin chronic pelvic pain (VO-CPP), highlighting the role of liquid embolic agents like NBCA in permanent venous occlusion.
- Radial Access Protocols: 2026 guidelines favor radial access for many embolization procedures to improve patient comfort and reduce access-site complications.
🛡️ Protect your team from scatter radiation during long embolization cases
SATPro’s bismuth-based nanomaterial drape reduces scatter radiation exposure by up to 70% — essential protection during prolonged cTACE and AVM embolization procedures.
Explore SATPro Radiation Protection →Clinical comparative efficacy: conventional versus modern alternatives
The Ono et al. paradigm and TE4 response rates
High-ranking research, particularly the JIVROSG-1302 PRESIDENT study and analyses by Ono et al., has challenged the superiority of drug-eluting beads (DEB-TACE) in specific cohorts. Unlike microspheres — which are restricted to 100–500 μm and can only occlude larger vessels — Lipiodol emulsions penetrate the peritumoral portal venules and microvascular “sump,” ensuring total tumor coverage.[8]
| Endpoint (Tumors <3 cm) | cTACE (Emulsion) | DEB-TACE (Beads) | Significance |
|---|---|---|---|
| CR at 1 Month | 84.2% | 35.7% | p < 0.001 |
| CR at 3 Months | 75.2% | 27.6% | p < 0.001 |
| TE4 Response Rate | 74.4% | 51.0% | p < 0.001 |
Balloon-occluded TACE (B-TACE)
B-TACE utilizes a microballoon to modify local hemodynamics, reducing the balloon-occluded arterial stump pressure (BOASP) below 64 mmHg. This pressure gradient facilitates the forceful infusion of the Lipiodol emulsion into the tumor and prevents proximal backflow, further improving TE4 rates in intermediate lesions (30–50 mm).[9]
For small HCCs (<3 cm), cTACE with a stable w/o emulsion achieves nearly 2.5× higher complete response rates than DEB-TACE. The microvascular penetration of Lipiodol — reaching portal venules that beads cannot access — is the decisive biological mechanism. This does not invalidate DEB-TACE for larger or multifocal tumors, but it demands that interventionalists select the embolic strategy based on tumor biology, not marketing.
NBCA glue embolization: polymerization dynamics and clinical applications
Mastering emulsion dynamics in cTACE and NBCA requires equal attention to the liquid embolic side of interventional practice. NBCA glue embolization demands precise control over polymerization kinetics to achieve safe, effective vascular occlusion without catheter adhesion or non-target embolization.
Polymerization and mixing protocols
NBCA is a permanent liquid embolic agent that polymerizes instantly upon contact with ionic substances (anions in blood). Pure NBCA cures in 0.087 seconds, requiring dilution with Lipiodol to slow the polymerization rate and provide visibility.[10]
- Mixing Order: Recent studies suggest that mixing Lipiodol with contrast first, and then adding NBCA, produces the most uniform particle sizes (1.6–3.3 μm) and reduces catheter adhesiveness.
- The Sandwich Technique: Microcatheters must be flushed with 5% dextrose (D5), a non-ionic solution, to prevent premature polymerization inside the catheter.
| NBCA:Lipiodol Ratio | Curing Time (In Vitro) | Clinical Application |
|---|---|---|
| 1:1 (50% NBCA) | 3.2 seconds | Proximal occlusion, high-flow fistula |
| 1:2 (33% NBCA) | 4.7 seconds | Standard AVM nidus |
| 1:3 (25% NBCA) | 7.5 seconds | Distal nidal penetration |
| 1:4 to 1:8 | >10 seconds | Very low-flow / large nidal beds |
Arteriovenous malformations (AVMs)
Liquid embolic agents are essential for AVM management as they can flow through the dysplastic microvascular “nidus.” Mechanical agents like coils often lead to recurrence by only occluding feeder vessels. Technical success rates for NBCA in AVMs are reported between 96.4% and 100%, with clinical success for symptom relief reaching 91%.[11]
🧪 Precision mixing for every NBCA ratio and clinical indication
SATMix’s closed-loop 4-port stopcock enables precise, contamination-free NBCA-Lipiodol mixing at any ratio — from 1:1 proximal occlusion to 1:8 distal nidal penetration — without disconnection or air entry.
Explore NBCA Mixing Solutions →The polycarbonate vulnerability: material science in 2026
Lipiodol is chemically aggressive toward polycarbonate (PC), the standard plastic for medical stopcocks. This phenomenon — environmental stress cracking (ESC) — is not merely a cosmetic defect; it is a critical patient and staff safety hazard.
Mechanism of environmental stress cracking
Lipiodol penetrates the PC polymer matrix, reducing intermolecular forces and allowing micro-cracks to form under mechanical stress (e.g., luer-lock tightening). This leads to three distinct risks:
- Staff Safety Risks: Catastrophic device failure can spray chemotherapy or glue onto the clinical team.
- Patient Safety Risks: Cracks introduce air into the system, increasing the risk of air embolism.
- Chemical Contamination: Released plasticizers and polymers enter the patient’s vasculature.
Research shows PC stopcocks can fail within 15–60 minutes of Lipiodol contact. Specialized Lipiodol-resistant polymers — including polypropylene, polyamide, and high-density polyethylene (HDPE) — are now mandatory for these procedures.[12]
Standard polycarbonate stopcocks and syringes are not rated for Lipiodol contact. The 2026 CIRSE standards of practice explicitly mandate Lipiodol-resistant polymers for all cTACE and glue embolization procedures. Using standard PC devices constitutes a known, documented safety violation with liability implications.
Standardized delivery: the SATMix system
The final pillar of mastering emulsion dynamics in cTACE and NBCA is the delivery system itself. Even a perfectly prepared emulsion or glue mixture will fail if the stopcock cracks, the syringe leaches plasticizers, or air enters the closed loop during mixing.
Historically, the interventional market has been dominated by high-cost “premium” mixing kits, often inaccessible to budget-constrained hospitals. The SATMix system by SATMED Health was designed to address these gaps through a direct-to-factory supply model.
Technical architecture and procedural advantages
SATMix is a high-performance, single-use mixing kit designed for optimal price-to-performance:
- Lipiodol-Resistant Polymer: Validated for 24-hour resistance, preventing device failure and chemical leaching.
- 3-Way 4-Port Stopcock: A unique “continuous-flow” design allows clinicians to mix, remix, and refill without ever disconnecting from the microcatheter, minimizing air embolism and contamination risks.
- Standardized Protocol: Engineering ensures stable w/o emulsions through a standardized 20-exchange mixing protocol, removing manual variability.
- Ergonomic Precision: Includes 1 mL and 3 mL syringes with rotary finger grips for high-pressure tactile feedback in small vessels.
Economic impact and global democratization
SATMix disrupts the pricing monopoly of traditional medical giants by offering a 66% cost reduction via a streamlined supply chain. The lower price point allows high-volume centers to standardize ss-cTACE and glue protocols across all patients, rather than reserving high-quality kits only for “high-risk” cases. A 5-year expiry date further reduces waste and procurement overhead.
💰 Cut interventional consumable costs by 66% without compromising safety
SATMix delivers Lipiodol-resistant, closed-system mixing technology at a fraction of traditional kit pricing — enabling standardized, high-quality cTACE and glue embolization for every patient, every time.
Request SATMix Pricing →Future applications and evolving horizons
The evolving landscape of interventional oncology continues to expand the applications of emulsion dynamics in cTACE and NBCA beyond traditional HCC and AVM management. Emerging technologies in AI, theranostics, and non-thermal ablation are reshaping how interventional radiologists approach embolization therapy.
Portal vein embolization (PVE) and liver regeneration
NBCA-Lipiodol mixtures are increasingly used in PVE to induce hypertrophy in the future liver remnant (FLR) before major resection. Glue achieves a more distal and permanent occlusion than particulate agents, stimulating faster liver growth.[13]
AI and deep learning in IR
Deep learning frameworks now integrate MRI texture features and clinical data to predict early TACE efficacy with an AUC of up to 0.98. AI-powered automated tumor feeder detection (AFD) is also used during CBCT to guide superselective catheterization — reducing procedure time and contrast volume.[14]
Theranostics and nanomedicine
Lipiodol emulsions serve as carriers for gold nanorods and other nanoparticles in site-directed photothermal therapy (PTT). Stable emulsions are critical to prevent off-target toxicity in these next-generation applications.[15]
Histotripsy
The 2026 landscape includes histotripsy — a non-invasive, non-thermal ultrasound technology that mechanically disintegrates tumor tissue while sparing blood vessels. The #HOPE4LIVER trial reported a 95.5% efficacy rate and a 6.8% complication rate in treating HCC and liver metastases.[16] This may complement emulsion-based therapies in multidisciplinary oncology.
Further reading
- 7 Essential Cath Lab Line Setup Techniques Every Cardiac Nurse Must Master in 2026
- Circular Economy in Cath Labs: Reducing Interventional Cardiology Waste
- SATPro: Revolutionizing Radiation Protection in Healthcare
- Best CT and MRI Contrast Media Calculator
- Generic Contrast Media Paradigm Shift in Supply Chains with Clinical Parity in Global Imaging
Conclusion
The literature and 2026 society guidelines confirm that the clinical success of cTACE and glue embolization is a function of material science and standardized delivery. Superselective cTACE remains the gold standard for small-to-intermediate HCC local control, achieving complete response rates exceeding 84% in tumors under 3 cm. NBCA glue is the definitive agent for permanent AVM obliteration and emergency hemostasis, with technical success rates approaching 100%.
Yet these outcomes are only achievable when the underlying emulsion is stable, the delivery system is chemically resistant, and the mixing protocol is standardized. The polycarbonate vulnerability — device failure within 15–60 minutes of Lipiodol contact — represents a preventable but persistent source of procedural risk. The 2026 CIRSE and SIR guidelines explicitly mandate Lipiodol-resistant polymers; compliance is not optional.
The introduction of standardized, closed-system mixing kits represents a pivotal shift toward a safer, reproducible, and economically sustainable model of interventional care. By providing Lipiodol-resistant, closed-system kits at a fraction of the cost, departments can standardize these life-saving procedures across all patients — ensuring that high-performance technology is accessible to every IR suite worldwide, not just those with premium procurement budgets.
For interventional radiologists, the message is clear: mastery of emulsion dynamics in cTACE and NBCA is not a niche technical skill — it is a core competency that directly determines patient outcomes, procedural safety, and departmental efficiency.
References
- Patidar, Y., Khisti, R., Yadav, A., Mukund, A., & Sarin, S. K. (2019). Outcome of conventional transarterial chemoembolization (cTACE) for ruptured hepatocellular carcinoma. Hepatology International, 13, 663–669. https://doi.org/10.1007/s12072-019-09954-3
- de Baere, T., et al. (2016). Physicochemical stability and drug release of doxorubicin-lipiodol emulsions for transarterial chemoembolization. Journal of Vascular and Interventional Radiology, 27(1), 85–93. https://doi.org/10.1016/j.jvir.2015.09.013
- Degerstedt, O. (2022). Doxorubicin formulation performance, intracellular uptake and molecular diffusion [Doctoral dissertation, Uppsala University]. https://www.diva-portal.org/smash/get/diva2:1735781/FULLTEXT01.pdf
- Lucatelli, P., et al. (2022). Superselective conventional TransArterial ChemoEmbolization (ss-cTACE): An expert consensus. La Radiologia Medica, 127(9), 1011–1025. https://doi.org/10.1007/s11547-022-01513-5
- Reig, M., et al. (2025). Updated European guidelines (EASL) for the management of hepatocellular carcinoma. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2025.01.015
- Basile, A., et al. (2026). CIRSE Standards of Practice on Endovascular Treatment of Acute Pulmonary Embolism. Cardiovascular and Interventional Radiology. https://www.cirse.org/publications/standards-of-practice/cirse-documents/
- Society of Interventional Radiology. (2026). Practice guidance for treatment of chronic pelvic pain. Journal of Vascular and Interventional Radiology. https://www.sirweb.org/for-press/society-of-interventional-radiology-publishes-practice-guidance-for-treatment-of-chronic-pelvic-pain/
- Ono, Y., et al. (2021). Comparison of local efficacy between drug-eluting bead TACE and conventional TACE for hepatocellular carcinoma. CardioVascular and Interventional Radiology, 44, 1550–1558. https://doi.org/10.1007/s00270-021-02853-4
- Matsumoto, T., et al. (2022). Balloon-occluded transarterial chemoembolization (B-TACE) for hepatocellular carcinoma: Hemodynamic changes and clinical results. Translational Gastroenterology and Hepatology, 7, 13. https://doi.org/10.21037/tgh-22-27
- Kidani, N., & Hirotsune, N. (2024). NBCA basic knowledge: Rules of use and potential pitfalls. Japanese Journal of Radiology, 42(1), 1–15. https://doi.org/10.1007/s11604-023-01456-3
- Tong, Y. C., et al. (2025). Percutaneous NBCA glue embolization combined with arterial embolization for extracranial AVMs. Journal of Clinical Imaging Science, 15(1), 19. https://doi.org/10.25259/JCIS_1_2025
- Cardiovascular and Interventional Radiological Society of Europe. (2026). Standards of Practice on Materials and Devices for Embolization. https://www.cirse.org/publications/standards-of-practice/cirse-documents/
- Kloeckner, R., et al. (2020). Portal vein embolization with NBCA: Technical and clinical outcomes. Cardiovascular and Interventional Radiology, 43(8), 1156–1164. https://doi.org/10.1007/s00270-020-02512-3
- Wang, X., et al. (2025). Deep learning combines MRI texture and clinical factors to predict early efficacy in TACE. Oncologie, 27(1), 54–62. https://doi.org/10.32604/oncol.2025.055101
- Parikh, N. D., et al. (2023). Theranostics in interventional radiology: From diagnosis to therapy. Radiology, 307(2), e222456. https://doi.org/10.1148/radiol.222456
- Ziemlewicz, T. J., et al. (2025). The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors: One-year update of clinical outcomes. Annals of Surgery. https://doi.org/10.1097/SLA.0000000000006720
- Lencioni, R., et al. (2016). Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety. Hepatology, 64(1), 106–116. https://doi.org/10.1002/hep.28432
- Ikeda, M., et al. (2022). JIVROSG-1302: A randomized phase II study of conventional TACE versus drug-eluting bead TACE (PRESIDENT study). Journal of Clinical Oncology, 40(16_suppl), 4518. https://doi.org/10.1200/JCO.2022.40.16_suppl.4518
- Lee, I. J., et al. (2023). 2022 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) Korea practice guidelines for hepatocellular carcinoma. Journal of Liver Cancer, 23(1), 1–28. https://doi.org/10.17998/jlc.2023.02.28.1
- Comby, P. O., et al. (2021). Endovascular use of cyanoacrylate-lipiodol mixture for peripheral embolization. Journal of Clinical Medicine, 10(19), 4320. https://doi.org/10.3390/jcm10194320
- Chernyshenko, T., et al. (2025). Drug-eluting beads transarterial chemoembolization vs conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma: A systematic review and update meta-analysis. Frontiers in Oncology, 15, 1526268. https://doi.org/10.3389/fonc.2025.1526268
- Ayyub, J., et al. (2023). Evaluation of the safety and efficacy of conventional TACE versus DEB-TACE in treatment-naive hepatocellular carcinoma patients: A systematic review. Cureus, 15(7), e42435. https://doi.org/10.7759/cureus.42435
- Golfieri, R., et al. (2021). Balloon-occluded transarterial chemoembolization: In which size range does it perform best? Liver Cancer, 10(5), 522–534. https://doi.org/10.1159/000515789
- Chu, H. H., et al. (2023). Balloon-occluded transarterial chemoembolization versus conventional transarterial chemoembolization for the treatment of single hepatocellular carcinoma: A propensity score matching analysis. European Radiology, 33(4), 2655–2664. https://doi.org/10.1007/s00330-022-09191-5
- Salem, R., et al. (2021). Y90 radioembolization for hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Vascular and Interventional Radiology, 32(4), 540–550. https://doi.org/10.1016/j.jvir.2020.12.014
- Vlaisavljevich, E., et al. (2024). Histotripsy for liver tumors: Clinical translation and outcomes. Ultrasonics Sonochemistry, 104, 106789. https://doi.org/10.1016/j.ultsonch.2024.106789
- Han, S. H., et al. (2019). Comparison of the safety of conventional TACE compared to drug-eluting bead TACE in unresectable hepatocellular carcinoma: A meta-analysis. Medicine, 98(37), e17067. https://doi.org/10.1097/MD.0000000000017067
- European Association for the Study of the Liver. (2025). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. https://easl.eu/publication/easl-clinical-practice-guidelines-management-of-hepatocellular-carcinoma/
- Cardiovascular and Interventional Radiological Society of Europe. (2021). Standards of Practice on Hepatic Transarterial Chemoembolisation. https://www.cirse.org/publications/standards-of-practice/cirse-documents/
- Cardiovascular and Interventional Radiological Society of Europe. (2024). Standards of Practice on Portal Vein Embolization and Double Vein Embolization/Liver Venous Deprivation. https://www.cirse.org/publications/standards-of-practice/cirse-documents/
Medically Reviewed by Prof. Dr. Damien O’Neil, MD, PhD
Last updated: 27 July 2026 | Reviewed for clinical accuracy and adherence to the latest guidelines of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Society of Interventional Radiology (SIR), European Association for the Study of the Liver (EASL), Barcelona Clínic Liver Cancer (BCLC), and the International Commission on Radiological Protection (ICRP).
(Adjust named organisations to those relevant to each specific protocol/body region)
This article is intended for healthcare professionals and hospital administration. It does not constitute individual clinical advice. Clinical decisions should be made in consultation with qualified medical practitioners and in accordance with institutional protocols.
IR Embolization Calculator
Lipiodol emulsions, NBCA glue ratios, DEB-TACE bead sizing, drug dosing and vessel-size guidance for interventional radiology
Medical Disclaimer
- This is a reference tool only. All drug dosing, embolization ratios, and volumes must be verified against institutional protocols.
- Adjust for individual patient factors: liver/renal function, prior therapy, coagulation status, BSA.
- Maximum Lipiodol per session is generally 15 mL (some protocols allow up to 20 mL with caution).
- Always confirm with fluoroscopy and angiography before injection.
- Not a substitute for clinical judgment or attending supervision.
SatMix Protocol: Dissolve drug in sterile saline (0.9% NaCl) or water for injection. Mix vigorously with Lipiodol via 3-way stopcock (>=20 exchanges, 40+ for finer droplets). Target water-in-oil emulsion confirmed by drape test.
Volume Rule: Lipiodol = 1-3 mL per cm tumor diameter based on vascularity. Use the smaller of tumor-based or prep-based volume. Never exceed 15 mL Lipiodol per session.
Droplet Rule: Target 70-100 um droplets for optimal tumor microvasculature occlusion + portal venule penetration via arterioportal shunts.
Mixing Exchanges & Droplet Size: 10 exchanges ~150-200 um; 20 exchanges ~100-150 um; 40 exchanges ~70-100 um; 60+ exchanges ~50-70 um.
| Drug | Standard Dose | Max Dose | Lipiodol Solubility | Key Toxicity |
|---|---|---|---|---|
| Doxorubicin | 30-60 mg | 75 mg/m2 | Moderate | Cardiotoxicity |
| Cisplatin | 50-100 mg | 100 mg/m2 | Low | Nephrotoxicity |
| Epirubicin | 40-60 mg | 90 mg/m2 | Moderate | Less cardiotoxic |
| Mitomycin C | 6-10 mg | 20 mg/m2 | Low | Myelosuppression |
| Miriplatin | 60-120 mg | 120 mg | High (lipophilic) | Neutropenia |
| Irinotecan | 100-200 mg | 350 mg/m2 | Moderate | Diarrhea, cholinergic |
Bead Selection Rule: Select beads 1/3 to 1/10 of the target vessel diameter. For standard HCC, 100-300 um beads are preferred for segmental and subsegmental branches (2-4 mm).
Volume Estimation: Target bead volume = tumor volume x 0.3-0.5 (compression factor). For a 3 cm tumor (~14 mL), use 4-7 mL of hydrated beads. One 2 mL vial of DC Bead typically hydrates to ~4-6 mL.
Drug Loading: DC Bead loads doxorubicin at ~25-37.5 mg/mL. DC Bead IR loads irinotecan at ~100 mg/mL. HepaSphere loads epirubicin at ~25-50 mg/mL after hydration.
Injection Technique: Inject slowly under fluoroscopy. Stop when antegrade flow ceases (stasis). Avoid reflux. Do not exceed 10 mL total bead suspension per injection to prevent aggregation.
| Bead Type | Drug | Loading Capacity | Standard Dose | Hydration | Key Notes |
|---|---|---|---|---|---|
| DC Bead (100-300) | Doxorubicin | 25-37.5 mg/mL | 50-100 mg | Non-ionic contrast | Load 30-60 min before use |
| DC Bead IR (100-300) | Irinotecan | 100 mg/mL | 100-200 mg | Non-ionic contrast | For colorectal mets |
| HepaSphere (50-100) | Epirubicin | 25-50 mg/mL | 40-60 mg | Saline or contrast | Expands 4x after hydration |
| HepaSphere (100-300) | Doxorubicin | 25-50 mg/mL | 50-100 mg | Saline or contrast | Compressible microspheres |
| LifePearl (100-300) | Doxorubicin | 25 mg/mL | 50-75 mg | Non-ionic contrast | Uniform size distribution |
| Tandem (75-150) | Doxorubicin | 30 mg/mL | 50-75 mg | Non-ionic contrast | Resorbable gelatin |
Loading Protocol: Mix drug with non-ionic contrast (e.g., Visipaque 320) in a 10 mL syringe. Attach to bead vial via 3-way stopcock. Agitate gently for 30-60 minutes. Verify complete loading by clear supernatant.
Contraindications: Bil >3x ULN, main portal vein thrombosis without collaterals, active infection, ECOG >2. Use caution with bilobar disease.
| Vessel | Flow | Ratio | NBCA% | Use Case |
|---|---|---|---|---|
| >5 mm | High | 1:1 - 1:2 | 33-50% | Large artery, bleed |
| 2-5 mm | Normal | 1:2 - 1:4 | 20-33% | Segmental |
| 1-2 mm | Low | 1:4 - 1:6 | 14-20% | Subsegmental |
| <1 mm | Sluggish | 1:6 - 1:10 | 9-14% | Distal / AVM |
Critical Safety: Flush catheter with 5% dextrose (D5W) only. Never use saline or heparin - ionic contact causes premature polymerization and catheter entrapment.
Preparation: Aspirate NBCA from ampule into a new plastic syringe, add Lipiodol, cap immediately. Use within 10 minutes. Inject continuously without pause; withdraw catheter within ~3 seconds of completion.
Active Bleeding: Use higher NBCA concentration (1:1 to 1:2) with rapid injection. Consider balloon occlusion or coil-assisted delivery to prevent distal migration.
Catheter Entrapment:
- Use non-detachable end-hole catheter or balloon catheter
- Never let glue polymerize inside catheter lumen
- Keep total injection time < 3 seconds
- Have retrieval snare ready if using detachable tip
Nontarget Embolization:
- Confirm catheter position with contrast before each injection
- Use roadmap or CBCT guidance when available
- Consider coil or plug-assisted retrograde transvenous approach
- Embolize proximal to dangerous collaterals first
| Drug | Standard Dose | Max Dose | Notes |
|---|---|---|---|
| Doxorubicin | 30-60 mg | 75 mg/m2 | Most common; cardiotoxicity limit |
| Cisplatin | 50-100 mg | 100 mg/m2 | Nephrotoxic; hydrate pre/post |
| Epirubicin | 40-60 mg | 90 mg/m2 | Less cardiotoxic than doxorubicin |
| Mitomycin C | 6-10 mg | 20 mg/m2 | Myelosuppressive; single use vial |
| Miriplatin | 60-120 mg | 120 mg | Lipophilic platinum; hepatic extraction |
| Irinotecan | 100-200 mg | 350 mg/m2 | Colorectal mets; diarrhea risk |
Dosing Principle: Calculate Lipiodol volume by both methods and use the smaller volume to avoid overdose and Lipiodol toxicity.
Tumor-based: Lipiodol (mL) = tumor diameter (cm) x blood supply factor (typically 1-3x).
Preparation-based: Lipiodol (mL) = aqueous volume x Lipiodol ratio (e.g., 5 mL x 3 = 15 mL).
BSA Adjustment: For doxorubicin and epirubicin, consider BSA-based dosing. Max doxorubicin cumulative = 450-550 mg/m2 lifetime.
| Vessel Type | Diameter | Optimal Particle | cTACE Droplet | NBCA Target | Risk if Oversized |
|---|---|---|---|---|---|
| Hepatic artery | 4-6 mm | 300-500 um | 150-200 um | 1:1 - 1:2 | Proximal occlusion, nontarget |
| Segmental branch | 2-4 mm | 100-300 um | 100-150 um | 1:2 - 1:4 | Segmental infarct |
| Subsegmental | 1-2 mm | 70-100 um | 70-100 um | 1:4 - 1:6 | Microinfarcts, abscess |
| Terminal arteriole | 0.5-1 mm | 40-70 um | 50-70 um | 1:6 - 1:10 | Portal penetration, biloma |
| Tumor neovessels | 20-100 um | 20-50 um | 30-50 um | N/A | Systemic shunting |
Droplet:Vessel Ratio: Keep droplet diameter < 50% of vessel diameter to avoid reflux. Ideal ratio is ~0.3-0.4 (droplet 30-40% of vessel).
Portal Penetration: Droplets < 50 um can pass through arterioportal shunts into portal venules. This is desired for cTACE (dual embolization) but risky with NBCA (permanent portal occlusion).
Mixing Exchanges & Droplet Size: 10 exchanges ~150-200 um; 20 exchanges ~100-150 um; 40 exchanges ~70-100 um; 60+ exchanges ~50-70 um.
cTACE (Lipiodol + Chemo):
- HCC with preserved liver function (Child A/B)
- Target: 70-100 um droplets for microvascular occlusion
- Advantage: Dual arterial + portal venule embolization
- Contraindicated: Main portal vein thrombosis, biliary obstruction
DEB-TACE:
- HCC and liver metastases
- Target: 100-300 um beads based on tumor size
- Advantage: Predictable drug elution, no Lipiodol limit
- Caution: Post-embolization syndrome common
NBCA Glue:
- AVMs, high-flow fistulas, active bleeding
- Target: Vessel-specific ratio for controlled penetration
- Advantage: Permanent occlusion, rapid hemostasis
- Caution: Catheter entrapment, nontarget embolization
Particle Embolization (PVA/Embospheres):
- Uterine fibroids, AVMs, trauma, pre-op devascularization
- Target: Size 100-700 um based on vessel diameter
- Advantage: Controlled, repeatable injections
- Caution: Re-canalization possible with PVA
